Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Technosphere Insulin 10U+ 20U · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TI 30 units (10 unit + 20 unit | EXPERIMENTAL | Technosphere® Insulin 30 units given as 2 cartridges: one 10 unit cartridge + one 20 unit cartridge |
| TI 30 units (30 unit cartridge | EXPERIMENTAL | Technosphere® Insulin 30 units given as one 30 unit cartridge |
| Name | Type | Description |
|---|---|---|
| Technosphere® Insulin 10U + 20U | DRUG | Inhaled Insulin |
| Technosphere® Insulin 30U | DRUG | Inhaled Insulin |
Inclusion Criteria: * Men and women aged 18 to 45 years, considered healthy based on screening physical examination, medical history, clinical chemistry, and urinalysis * No smoking in the past 6 months (including cigarettes, cigars, and pipes) * Urine cotinine testing \< 100 ng/mL * Body mass inde...
Technosphere Insulin 10U+ 20U is an investigational inhaled insulin product developed by MannKind Corporation. It is a small molecule formulation studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease indications studied for this product have not been disclosed.
Technosphere Insulin 10U+ 20U is made by MannKind Corporation, which trades on the Nasdaq under the ticker MNKD. MannKind is the developer of the Technosphere insulin delivery technology used in this product.
Technosphere Insulin 10U+ 20U is in Phase 1 clinical development. It is an investigational product and is not approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this specific product.
Technosphere Insulin 10U+ 20U has been studied in one completed Phase 1 trial, NCT01902121, titled "Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge." The trial enrolled 40 healthy adult volunteers in the United States and used a controlled, randomized design.